Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
Date:2/10/2011

clinical candidates will not proceed to later stage clinical trials; and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2009 and Form 10-Q for the quarter ended September 30, 2010. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.NEUROCRINE BIOSCIENCES, INC.Condensed Consolidated Statements of Operations(in thousands, except for per share data)Three Months Ended
December 31,Year Ended
December 31,2010200920102009(unaudited)(unaudited)Revenues:Sponsored research and development

$ 4,419$   11$10,938$
34License fees and milestones

9,23872922,5632,919Total revenues

13,65774033,5012,953Operating expenses:Research and development

8,0656,75331,15133,722General and administrative

3,3232,84113,27314,360Cease-use expense

2,3981262,7995,984Restructuring expense

———2,557Total operating expenses

13,7869,72047,22356,623Loss from operations

(129)(8,980)(13,722)(53,670)Other income:Gain on sale of fixed assets

92108294841Other income, net

2,5249565,4601,791Total other income

2,6161,0645,7542,632Net income (los
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
2. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
3. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
4. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
8. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
9. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
10. Neurocrine Biosciences Amends Corporate Headquarters Lease
11. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Avure Technologies celebrates a year of success and ... its fleet of high volume High Pressure Processing (HPP) systems. ... return to PackExpo this year, which is where we first ... Jeff Williams, CEO at Avure. “Sales of the new Avure ... meeting the challenges of market demand for higher throughput. We ...
(Date:10/30/2014)... 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a company overview at the Nomura Biotechnology ... in Boston, MA. A ... "Investors & Media" section of the Company,s website, www.isispharm.com ... within 48 hours and will be archived for a limited ...
(Date:10/30/2014)... RIDGE, N.J. , Oct. 30, 2014  Regado ... that it will hold a conference call and live ... a.m. EST to discuss its third quarter 2014 financial ... the conference call by dialing (888) 347-1165 for domestic ... call will be webcast live under the investor relations ...
(Date:10/30/2014)... (Oct. 29, 2014) – The severe flooding that devastated ... been less destructive if the bridges, roads and other ... new study from the University of Colorado Denver. , ... infrastructure," said Jimmy Kim, PhD, associate professor of structural ... Applied Science and lead author the study. "There is ...
Breaking Biology Technology:In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2
... DIEGO, Aug. 21 NovaRx Corporation announced ... III clinical trial of,Lucanix(R) (belagenpumatucel-L) in the ... The first patient enrolled in the study ... principal investigator at the University,of California, San ...
... Arpida Ltd.,(SWX: ARPN) today announced that the ... its Marketing Authorisation Application (MAA) for,intravenous iclaprim. ... in,the European Union for the treatment of ... is a hospital antibiotic drug candidate with,potent ...
... iron are the basis for much of mankind,s technology, ... this week,s issue of the journal Nature ... and industrial researchers from the UK, USA and Lesotho, ... small amount of another common metal, manganese, to create ...
Cached Biology Technology:NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 2NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 3NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 4Arpida's iclaprim MAA Accepted for Review by EMEA 2Arpida's iclaprim MAA Accepted for Review by EMEA 3Creating unconventional metals 2
(Date:10/31/2014)... out of a nagging mystery about the development of animal ... why animal species didn,t flourish sooner, once sufficient oxygen covered ... of the Proterozoic period, about 800 million years ago — ... researchers think there also was plenty of oxygen? , Well, ... , In a study published Oct. 30 in Science ...
(Date:10/31/2014)... green space in cities is good for attracting species, but ... environments, a University of Iowa study has found. , The ... in Iowa, and recorded the abundance of two insects that ... of the trees, black cherry and black walnut, they didn,t ... fruit flies that feed on the walnuts and black cherries ...
(Date:10/31/2014)... uncovered key steps involved in programmed cell death, offering ... cancers and neurodegenerative diseases. , The research teams ... to discover the three-dimensional structure of a key cell ... in how it causes cell death. Their studies were ... Proceedings of the National Academy of Sciences ...
Breaking Biology News(10 mins):Lack of oxygen delayed the rise of animals on Earth 2Green spaces don't ensure biodiversity in urban areas 2A matter of life and death: Cell death proteins key to fighting disease 2
... are developing a cost-effective electronic monitoring system that will ... ecosystems by allowing users to track water-quality data from ... a National Science Foundation (NSF) grant. "Our goal ... environmental conditions in the Chesapeake Bay, the sounds of ...
... to help the government cut through red tape and roll ... This week, the university,s Durham Energy ... meet with the Department of Energy & Climate Change to ... on Wednesday November 3rd will also be attended by Ofgem ...
... Calif., Nov. 1, 2010 General Manifolds LLC, a ... that the United States Patent and Trademark Office has ... method for simulating functions within the cerebral cortex of ... a broad range of applications from artificial intelligence to ...
Cached Biology News:Researchers developing real-time electronic monitoring for coastal waters 2Durham Energy Institute to advise government on green technology 2General Manifolds LLC Announces Issuance of US Patent in Computational Neuroscience 2
... Service The Human Genetic Cell Bank ... (EBV) immortalisation of human peripheral blood lymphocytes ... cell lines (LCLs). These cell lines are ... source of genomic DNA and RNA. ...
... Extract Protein Array Kit is designed for ... The expression of a protein in an ... antibody. When the antibody binds the protein, ... chemiluminescent or fluorescent signal created by directly ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
... is specifically formulated for mounting tissue specimens, ... stained with immunohistochemical methods for viewing by ... with chromogens, such as AEC, that are ... dries completely when slides are cover-slipped forming ...
Biology Products: